As time has marched on, I’ve seen more and more impressive training programs pop up across the BioHealth Capital Region and the nation. Everything from specialized biotech training courses such as Bio-Trac to incredible biotech-focused associate degrees such as those offered through Montgomery College, Frederick Community College, and the Universities at Shady Grove. Communities colleges are partnering with nearby industries and offering internships and apprenticeships, some of which actually pay for students’ tuition and all but guarantee a job after finishing.
To add to the growing list of recent life science real estate developments in Greater Philadelphia, this week Scheer Partners shared that SkyREM, a real estate investor, owner, and developer with properties across the country, has big plans to convert Philly’s historic Quartermaster site into the Quartermaster Science + Technology Park. The $250 million commercial redevelopment project will include both wet and dry lab space catering to early-stage life science startups as well as more established companies.
Matt has over 30 years of experience in life sciences, business development, and entrepreneurship. He has founded and directed numerous companies, including ones that manufacture, wholesale, warehouse, and sell products on an industrial scale, as well as companies that perform environmental and analytical testing.
Philadelphia-based Context Therapeutics reported that its clinical collaborator, Stemline Therapeutics, had its Orserdu (elacestrant) approved by the FDA. Stemline Therapeutics is a U.S.-based, wholly-owned subsidiary of Italy’s The Menarini Group.
West Conshohocken, Pa.-based Keystone, a commercial real estate development and investment company, is more than doubling lab space in Philadelphia’s Center City. The company recently announced the expansion of its laboratory space at The Curtis, adding 200,000 square feet to provide more than 325,000 square feet.
XyloCor Therapeutics, based in Wayne, Pa., recently announced its Phase I/II EXACT trial has wrapped the Phase II portion of the study. The trial was evaluating the company’s lead gene therapy candidate XC001 (encoberminogene rezmadenovic) in patients with refractory angina.
Despite its challenges, 2022 still proved to be an exciting year for life science real estate in the City of Brotherly Love. Companies announced various new projects throughout Philadelphia, targeting niches like university graduates and biomanufacturing. While experts say the city’s growth is due to slow down, it’s impossible not to acknowledge the leaps and bounds Philly has made recently.
Rise Therapeutics Announces FDA Clearance of its IND Application to Initiate a Phase 1 Study of an Oral Immunotherapy for the Treatment of Ulcerative Colitis
Rise Therapeutics Announces FDA Clearance of its IND Application to Initiate a Phase 1 Study of an Oral Immunotherapy for the Treatment of Ulcerative Colitis 31 January 2023
Rockville, Maryland, January 31st, 2023 – Rise Therapeutics, a biopharmaceutical company engaged in developing novel oral synthetic biology medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a Phase 1 clinical trial of its lead program candidate, R-3750.
R-3750 is a synthetic biology-based cellular immunotherapy being developed for the treatment of Inflammatory Bowel Disease (IBD). Optimized for intestinal delivery of a key microbiome-associated immune regulatory molecule whose natural role is to control host immune function, R-3750 is an oral therapy that has the potential to treat the underlying immunological basis of gastrointestinal-associated inflammatory disease. R-3750 leverages Rise Therapeutics’ proprietary drug delivery platform to orally deliver targeted biological therapy that engages a specific receptor expressed on dendritic cells, reducing inflammation and inducing colonic immune homeostasis. As a result, R-3750 improves gut membrane barrier integrity reestablishing a normal microbiome composition.
The Phase 1 trial will be a single and repeat dose study assessing the safety and tolerability, drug exposure, and clinical…
Vector BioMed Launches in Maryland with Gene Therapy Industry Veteran at Helm to Address the Vector Supply Bottleneck with End-to-End Solutions Platform
Biomanufacturing Company Vector BioMed Launches with Mission to Provide Access to High-Quality Lentiviral Vectors and Address the Vector Supply Bottleneck
NEWS PROVIDED BY
Jan 31, 2023, 07:30 ET
SHARE THIS ARTICLE
First Round Funding Led by Viking Global Investors and Casdin Capital
Boro Dropulić, Ph.D., MBA, named Chief Executive Officer of Vector BioMed
GAITHERSBURG, Md., Jan. 31, 2023 /PRNewswire/ — Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced its launch and first financing round led by Viking Global Investors and Casdin Capital. The funds will support the acceleration of commercial operations to provide rapid access to high-quality lentiviral vectors for pre-clinical development, clinical trials, and commercialization.
In contrast to traditional contract development and manufacturing organizations (CDMOs), Vector BioMed is a solution provider that will provide partners with the capabilities to take their lentiviral vector-based medicinal concepts into the clinic and accelerate their path to commercialization. Vector BioMed will help address the industry’s current vector supply bottleneck by providing lentiviral vectors at scale, while also offering turnkey solutions for vector design and optimization, pre-clinical manufacturing, GMP manufacturing, and other support services.
In conjunction with the funding and launch, co-founder Boro Dropulić, Ph.D., MBA has…
Deka Biosciences Receives FDA Clearance of DK210 (EGFR) Investigational New Drug Application GERMANTOWN, Md., Jan. 30, 2023 /PRNewswire/ — Deka Biosciences (“Deka”), a biotech company focused on developing novel cytokine therapies to [….]